Daily topical tacrolimus therapy prevents skin rejection in a rodent hind limb allograft model

Plastic and Reconstructive Surgery

Volumn 123, Issue SUPPL.2S, 2009, Pages

  Lee, W P Andrew ^a   Solari, Mario G ^a   Washington, Kia M ^a   Sacks, Justin M ^a   Hautz, Theresa ^a   Unadkat, Jignesh V ^a   Horibe, Elaine K ^a   Venkataramanan, Raman ^a   Larregina, Adriana T ^a   Thomson, Angus W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; LYMPHOCYTE ANTIBODY; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELLULAR IMMUNITY; COMPOSITE GRAFT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MUSCLE LEVEL; HINDLIMB; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEWIS RAT; MALE; MORBIDITY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; RODENT; SKIN ALLOGRAFT; SURVIVAL; T CELL DEPLETION; TISSUE GRAFT; TOPICAL TREATMENT; TREATMENT DURATION; WISTAR FURTH RAT; ANIMAL; ARTICLE; DISEASE MODEL; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGY; SKIN; SKIN TRANSPLANTATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HINDLIMB; IMMUNOSUPPRESSIVE AGENTS; MALE; RATS; RATS, INBRED LEW; RATS, INBRED WF; SKIN; SKIN TRANSPLANTATION; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 61749088006     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318191bcbd     Document Type: Conference Paper

References (27)

1. Lanzetta M, Petruzzo P, Dubernard JM, et al. Second report (1998-2006) of the International Registry of Hand and Composite Tissue Transplantation. Transpl Immunol. 2007;18:1.
2. U.S. Food and Drug Administration. FDA application no. (NDA) 050777: Protopic, Astellas, original approval December 8, 2008.
3. Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmaco-therapy 2007;27:1020.
4. Margreiter R, Brandacher G, Ninkovic M, Steurer W, Kreczy A, Schneeberger S. A double-hand transplant can be worth the effort! Transplantation 2002;74:85.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245.
6. Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004; 114:137.
7. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 2001;107:519.
8. Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epi-dermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol. 2001;107:345.
9. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2005;115:1276.
10. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/ toxic epidermal necrolysis. Br J Dermatol. 2006;155:722.
11. Lee WP, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg. 1991;87:401.
12. Tung TH, Mohanakumar T, Mackinnon SE. TH1/TH2 cytokine profile of the immune response in limb component transplantation. Plast Reconstr Surg. 2005;116:557.
13. Buttemeyer R, Jones NF, Min Z, Rao U. Rejection of the component tissues of limb allografts in rats immunosup-pressed with FK-506 and cyclosporine. Plast Reconstr Surg. 1996;97:139.
14. Boyse EA, Old LJ. Loss of skin allograft tolerance by chimeras. Transplantation 1968;6:619.
15. Fuchimoto Y, Gleit ZL, Huang CA, et al. Skin-specific alloan-tigens in miniature swine. Transplantation 2001;72:122.
16. Steinmuller D, Lofgreen JS. Differential survival of skin and heart allografts in radiation chimaeras provides further evidence for Sk histocompatibility antigen. Nature 1974;248: 796.
17. Steinmuller D. The enigma of skin allograft rejection. Transplant Rev. 1998;12:42.
18. Mathes DW, Randolph MA, Solari MG, et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation 2003;75:25.
19. Hettiaratchy S, Melendy E, Randolph MA, et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation 2004;77:514.
20. Klaue P, Jolley WB. Prolonged survival of rabbit skin allo-grafts after treatment with locally applied triamcinolone ace-tonide in combination with small doses of systemic immu-nosuppressives. Transplantation 1972;13:53.
21. Inceoglu S, Siemionow M, Chick L, Craven CM, Lister GD. The effect of combined immunosuppression with systemic low-dose cyclosporin and topical fluocinolone acetonide on the survival of rat hind-limb allografts. Ann Plast Surg. 1994; 33:57.
22. Alexander JW, Craycraft TK. Prolongation of allogeneic skin survival by in vitro treatment with fluocinolone acetonide: Effect of incubation time and length of storage. J Trauma 1974;14:836.
23. Lai CS, Wesseler TA, Alexander JW, Babcock GF. Long-term survival of skin allografts in rats treated with topical cyclo-sporine. Transplantation 1987;44:83.
24. Tran HS, Malli D, Chrzanowski FA, Puc MM, Matthews MS, Hewitt CW. Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene gly-col-8 glyceryl caprylate/caprate. J Surg Res. 1999;83:136.
25. Black KS, Nguyen DK, Proctor CM, Patel MP, Hewitt CW. Site-specific suppression of cell-mediated immunity by cyclo-sporine. J Invest Dermatol. 1990;94:644.
26. Fujita T, Takahashi S, Yagihashi A, Jimbow K, Sato N. Prolonged survival of rat skin allograft by treatment with FK506 ointment. Transplantation 1997;64:922.
27. Weiss HM, Fresneau M, Moenius T, Stuetz A, Billich A. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: Implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36:1812.